Your browser is no longer supported. Please, upgrade your browser.
Settings
CVAC [NASD]
CureVac N.V.
Index- P/E- EPS (ttm)- Insider Own55.92% Shs Outstand177.97M Perf Week-9.06%
Market Cap9.35B Forward P/E8.89 EPS next Y5.54 Insider Trans0.00% Shs Float82.25M Perf Month-32.96%
Income- PEG- EPS next Q-0.72 Inst Own23.50% Short Float4.41% Perf Quarter-57.88%
Sales48.87M P/S191.24 EPS this Y-28.20% Inst Trans0.18% Short Ratio2.60 Perf Half Y-44.83%
Book/sh4.70 P/B10.48 EPS next Y5553.06% ROA- Target Price66.86 Perf Year-
Cash/sh8.22 P/C5.99 EPS next 5Y- ROE- 52W Range36.15 - 151.80 Perf YTD-39.24%
Dividend- P/FCF- EPS past 5Y- ROI-14.20% 52W High-67.55% Beta-
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin- 52W Low36.27% ATR3.26
Employees500 Current Ratio5.60 Sales Q/Q87.50% Oper. Margin- RSI (14)30.74 Volatility4.63% 5.26%
OptionableYes Debt/Eq0.08 EPS Q/Q-170.60% Profit Margin- Rel Volume0.54 Prev Close51.86
ShortableYes LT Debt/Eq0.07 Earnings- Payout- Avg Volume1.39M Price49.26
Recom2.70 SMA20-11.52% SMA50-37.39% SMA200-44.68% Volume750,054 Change-5.01%
Jun-17-21Downgrade BofA Securities Buy → Neutral $50
Apr-26-21Resumed Credit Suisse Underperform
Apr-26-21Initiated Guggenheim Neutral
Dec-10-20Downgrade Credit Suisse Neutral → Underperform $50 → $47
Sep-08-20Initiated Jefferies Hold $58
Sep-08-20Initiated Credit Suisse Neutral $68
Sep-08-20Initiated BofA Securities Buy $70
Jul-21-21 08:00PM  
Jul-20-21 11:01AM  
Jul-10-21 06:00AM  
Jul-07-21 12:56PM  
Jul-04-21 07:31AM  
06:00AM  
Jul-03-21 07:00AM  
06:15AM  
Jul-01-21 10:58AM  
09:03AM  
04:34AM  
03:52AM  
02:34AM  
02:15AM  
02:00AM  
Jun-30-21 04:59PM  
04:45PM  
04:30PM  
11:13AM  
07:12AM  
Jun-29-21 07:19AM  
Jun-25-21 12:35AM  
Jun-23-21 11:08AM  
07:45AM  
06:00AM  
05:55AM  
Jun-22-21 05:52AM  
Jun-21-21 07:29AM  
06:13AM  
04:09AM  
Jun-18-21 10:54AM  
10:40AM  
06:30AM  
06:18AM  
Jun-17-21 04:46PM  
04:29PM  
04:13PM  
04:01PM  
03:55PM  
12:36PM  
12:14PM  
11:20AM  
11:06AM  
10:41AM  
10:32AM  
10:30AM  
10:26AM  
10:19AM  
08:35AM  
08:17AM  
07:08AM  
06:44AM  
06:25AM  
05:07AM  
05:04AM  
04:09AM  
04:01AM  
02:27AM  
01:20AM  
01:13AM  
Jun-16-21 08:00PM  
07:31PM  
05:47PM  
05:00PM  
02:06PM  
Jun-11-21 11:23AM  
Jun-10-21 08:00PM  
02:47AM  
Jun-08-21 08:17AM  
08:10AM  
Jun-04-21 08:41PM  
Jun-02-21 11:17AM  
07:30AM  
Jun-01-21 08:11AM  
May-31-21 05:14PM  
May-28-21 04:50PM  
May-26-21 02:17PM  
10:16AM  
07:30AM  
May-21-21 10:27AM  
May-19-21 06:44AM  
May-13-21 05:21PM  
09:20AM  
07:45AM  
May-08-21 08:00AM  
May-07-21 04:30PM  
May-06-21 11:37AM  
09:58AM  
May-05-21 04:13AM  
May-01-21 11:05AM  
Apr-30-21 06:14AM  
Apr-26-21 01:54PM  
10:14AM  
09:04AM  
Apr-22-21 07:00AM  
Apr-21-21 06:30AM  
02:55AM  
Apr-20-21 10:49AM  
10:22AM  
Apr-19-21 07:45AM  
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tubingen, Germany.